Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B

Baiguo XU; Huiling XIANG; Tao HAN

doi:10.3969/j.issn.1001-5256.2021.02.039

Volume 37 Issue 2

Mar. 2021

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2021 > 37(2): 433-436

PDF( 1863 KB)

Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2021.02.039

Department of Hepatology and Gastroenterology, The Third Central Clinical College of Tianjin Medical University; Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases; Artificial Cell Engineering Technology Research Center; Tianjin Institute of Hepatobiliary Disease, Tianjin 300170, China

Received Date: 2020-08-03
Accepted Date: 2020-09-15
Published Date: 2021-02-20

Abstract

Abstract

Hepatitis B virus infection is one of the primary causes of liver cirrhosis and liver cancer. The use of antiviral drugs significantly reduces the risk of liver cancer in patients with chronic hepatitis B (CHB), but some of the patients who receive antiviral drugs for a long time still develop liver cancer. Therefore, it is necessary to early identify and predict the risk of liver cancer in such patients. Currently, several models for predicting the risk of liver cancer during antiviral therapy in CHB patients have been developed based on the risk factors such as liver cirrhosis, age, sex, liver stiffness, virology, serological markers, alcohol consumption, and history of diabetes, including REACH-B, PAGE-B, mPAGE-B, APA-B, CAMD, AASL, and REAL-B. This article reviews the research advances in the models for predicting the risk of liver cancer during antiviral therapy in CHB patients.
- Hepatitis B, Chronic,
- Liver Neoplasms,
- Risk Factors

FullText(HTML)

References(30)

References

[1]	Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: A systematic analysis for the global burden of disease study[J]. JAMA Oncol, 2017, 3(4): 524-548.
[2]	FORNER A, REIG M, BRUIX J. Hepatocellular carcinoma[J]. Lancet, 2018, 391(10127): 1301-1314. DOI: 10.1016/S0140-6736(18)30010-2
[3]	FATTOVICH G, BORTOLOTTI F, DONATO F. Natural history of chronic hepatitis B: Special emphasis on disease progression and prognostic factors[J]. J Hepatol, 2008, 48(2): 335-352. DOI: 10.1016/j.jhep.2007.11.011
[4]	CHAN SL, WONG VW, QIN S, et al. Infection and cancer: The case of hepatitis B[J]. J Clin Oncol, 2016, 34(1): 83-90. DOI: 10.1200/JCO.2015.61.5724
[5]	LIU K, CHOI J, LE A, et al. Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis[J]. Aliment Pharmacol Ther, 2019, 50(9): 1037-1048. DOI: 10.1111/apt.15499
[6]	WONG GL, WONG VW. Risk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapy[J]. World J Gastroenterol, 2013, 19(39): 6515-6522. DOI: 10.3748/wjg.v19.i39.6515
[7]	ARENDS P, SONNEVELD MJ, ZOUTENDIJK R, et al. Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians[J]. Gut, 2015, 64(8): 1289-1295. DOI: 10.1136/gutjnl-2014-307023
[8]	SERPER M, TADDEI TH, MEHTA R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality[J]. Gastroenterology, 2017, 152(8): 1954-1964. DOI: 10.1053/j.gastro.2017.02.040
[9]	KIM BH, LIM YS, KIM EY, et al. Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population[J]. J Gastroenterol Hepatol, 2018, 33(2): 475-483. DOI: 10.1111/jgh.13848
[10]	European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Hepatol, 2017, 67(2): 370-398.
[11]	TERRAULT NA, LOK A, MCMAHON BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. Hepatology, 2018, 67(4): 1560-1599. DOI: 10.1002/hep.29800
[12]	OMATA M, CHENG AL, KOKUDO N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: A 2017 update[J]. Hepatol Int, 2017, 11(4): 317-370.
[13]	Korean Association for the Study of the Liver. KASL clinical practice guidelines: Management of chronic hepatitis B[J]. Clin Mol Hepatol, 2016, 22(1): 18-75. DOI: 10.3350/cmh.2016.22.1.18
[14]	CADIER B, BULSEI J, NAHON P, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States[J]. Hepatology, 2017, 65(4): 1237-1248. DOI: 10.1002/hep.28961
[15]	CHANG TT, LAI CL, KEW YOON S, et al. Entecavir treatment for up to 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B[J]. Hepatology, 2010, 51(2): 422-430. DOI: 10.1002/hep.23327
[16]	LAI CL, GANE E, LIAW YF, et al. Telbivudine versus lamivudine in patients with chronic hepatitis B[J]. N Engl J Med, 2007, 357(25): 2576-2588. DOI: 10.1056/NEJMoa066422
[17]	MARCELLIN P, HEATHCOTE EJ, BUTI M, et al. Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B[J]. N Engl J Med, 2008, 359(23): 2442-2455. DOI: 10.1056/NEJMoa0802878
[18]	LEE HW, YOO EJ, KIM BK, et al. Prediction of development of liver-related events by transient elastography in hepatitis B patients with complete virological response on antiviral therapy[J]. Am J Gastroenterol, 2014, 109(8): 1241-1249. DOI: 10.1038/ajg.2014.157
[19]	JUNG KS, KIM SU, SONG K, et al. Validation of hepatitis B virus-related hepatocellular carcinoma prediction models in the era of antiviral therapy[J]. Hepatology, 2015, 62(6): 1757-1766. DOI: 10.1002/hep.28115
[20]	PAPATHEODORIDIS G, DALEKOS G, SYPSA V, et al. PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy[J]. J Hepatol, 2016, 64(4): 800-806. DOI: 10.1016/j.jhep.2015.11.035
[21]	KIM JH, KIM YD, LEE M, et al. Modified PAGE-B score predicts the risk of hepatocellular carcinoma in Asians with chronic hepatitis B on antiviral therapy[J]. J Hepatol, 2018, 69(5): 1066-1073. DOI: 10.1016/j.jhep.2018.07.018
[22]	CHEN CH, LEE CM, LAI HC, et al. Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir[J]. Oncotarget, 2017, 8(54): 92431-92441. DOI: 10.18632/oncotarget.21369
[23]	HSU YC, YIP TC, HO HJ, et al. Development of a scoring system to predict hepatocellular carcinoma in Asians on antivirals for chronic hepatitis B[J]. J Hepatol, 2018, 69(2): 278-285. DOI: 10.1016/j.jhep.2018.02.032
[24]	YU JH, SUH YJ, JIN YJ, et al. Prediction model for hepatocellular carcinoma risk in treatment-naive chronic hepatitis B patients receiving entecavir/tenofovir[J]. Eur J Gastroenterol Hepatol, 2019, 31(7): 865-872. DOI: 10.1097/MEG.0000000000001357
[25]	YANG HI, YEH ML, WONG GL, et al. Real-world effectiveness from the Asia Pacific Rim Liver Consortium for HBV risk score for the prediction of hepatocellular carcinoma in chronic hepatitis B patients treated with oral antiviral therapy[J]. J Infect Dis, 2020, 221(3): 389-399. DOI: 10.1093/infdis/jiz477
[26]	WU S, KONG Y, PIAO H, et al. On-treatment changes of liver stiffness at week 26 could predict 2-year clinical outcomes in HBV-related compensated cirrhosis[J]. Liver Int, 2018, 38(6): 1045-1054. DOI: 10.1111/liv.13623
[27]	CHIANG HH, LEE CM, HU TH, et al. A combination of the on-treatment FIB-4 and alpha-foetoprotein predicts clinical outcomes in cirrhotic patients receiving entecavir[J]. Liver Int, 2018, 38(11): 1997-2005. DOI: 10.1111/liv.13889
[28]	WONG GL, CHAN HL, TSE YK, et al. Normal on-treatment ALT during antiviral treatment is associated with a lower risk of hepatic events in patients with chronic hepatitis B[J]. J Hepatol, 2018, 69(4): 793-802. DOI: 10.1016/j.jhep.2018.05.009
[29]	KIM BG, PARK NH, LEE SB, et al. The risk of hepatocellular carcinoma within and beyond the first 5 years of entecavir in Korean patients with chronic hepatitis B[J]. Liver Int, 2018, 38(12): 2269-2276. DOI: 10.1111/liv.13938
[30]	HSU YC, JUN T, HUANG YT, et al. Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B[J]. Aliment Pharmacol Ther, 2018, 48(10): 1128-1137. DOI: 10.1111/apt.15006

Relative Articles

[1]	Shanshan XU, Lixia QIU, Yali LIU, Jing ZHANG. Risk factors and predictive models for liver cancer after sustained virologic response in hepatitis C[J]. Journal of Clinical Hepatology, 2024, 40(6): 1259-1263. doi: 10.12449/JCH240629
[2]	Yichen ZHU, Chunxia SHA, Chunsun FAN, Tiejun ZHANG. Risk factors for liver cancer in chronic hepatitis B patients and construction of a nomogram prediction model[J]. Journal of Clinical Hepatology, 2024, 40(12): 2441-2449. doi: 10.12449/JCH241214
[3]	Xiaoyan MA, Yun CHEN, Jiacheng LIU, Jie LI, Chao WU. Clinical features and related risk factors of chronic hepatitis B patients with concomitant minimal hepatic steatosis[J]. Journal of Clinical Hepatology, 2023, 39(1): 63-69. doi: 10.3969/j.issn.1001-5256.2023.01.010
[4]	Jiajia RUAN, Shifei WEN, Xia WANG, Li LI, Juanjuan FU, Xiucheng PAN. Influencing factors for recompensation in patients with first-time decompensated hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2022, 38(8): 1796-1800. doi: 10.3969/j.issn.1001-5256.2022.08.015
[5]	Bin WANG, Hansheng LIANG, Yi FENG, Youzhong AN. Risk factors for perioperative hypotension in severe patients after liver cancer surgery[J]. Journal of Clinical Hepatology, 2022, 38(3): 572-576. doi: 10.3969/j.issn.1001-5256.2022.03.015
[6]	Yu LIU, Xue MEI, Yuyi ZHANG, Ying ZOU, Zhengguo ZHANG, Hongying GUO, Wei YUAN, Jiefei WANG, Zhiping QIAN. Clinical features and risk factors of acute hepatitis E with severe jaundice[J]. Journal of Clinical Hepatology, 2021, 37(3): 565-569. doi: 10.3969/j.issn.1001-5256.2021.03.013
[7]	Long LIU, Ke SHI, Qun ZHANG, Chongping RAN, Jie HOU, Yi ZHANG, Xianbo WANG. Risk factors for hepatocellular carcinoma in patients with chronic hepatitis B[J]. Journal of Clinical Hepatology, 2021, 37(7): 1589-1593. doi: 10.3969/j.issn.1001-5256.2021.07.022
[8]	He CHEN, Juanjuan FU, Li LI, Guangde YANG, Xiucheng PAN. Influencing factors for low-level viremia in chronic hepatitis B patients treated with long-term entecavir antiviral therapy[J]. Journal of Clinical Hepatology, 2021, 37(3): 556-559. doi: 10.3969/j.issn.1001-5256.2021.03.011
[9]	Wang CaiBin, Su Yang. Risk factors for posthepatectomy liver failure and related prevention and treatment methods[J]. Journal of Clinical Hepatology, 2020, 36(9): 2119-2124. doi: 10.3969/j.issn.1001-5256.2020.09.048
[10]	Yao ChengZi, Feng Gong, Yu WenSi, Du Huan, Mi Man. Risk factors for the development and progression of nonalcoholic fatty liver disease[J]. Journal of Clinical Hepatology, 2020, 36(2): 433-436. doi: 10.3969/j.issn.1001-5256.2020.02.044
[11]	Ren DanDan, Liu Na, Zhou LuLu, Zhang Nan, Li ChunXia, Dong Bing, Xu GuangHua. Risk factors for hepatitis B virus-related hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2020, 36(7): 1634-1638. doi: 10.3969/j.issn.1001-5256.2020.07.041
[12]	Zheng WeiPing, Shen ZhongYang. Risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma and related control strategies[J]. Journal of Clinical Hepatology, 2019, 35(11): 2391-2395. doi: 10.3969/j.issn.1001-5256.2019.11.003
[13]	Liu HongJin, Bao ChunMei, Bai WenLin, Li YinYin, Rong GuangHua, Lu YinYing, Chen Yan, Liu Ze, Cheng JiaMin, Ceng Zhen. Risk factors for infectious complications in primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1033-1037. doi: 10.3969/j.issn.1001-5256.2018.05.021
[14]	Chang XiuJuan, Lu YinYing, Rong GuangHua, Liu Ze, Chen Yan, Xu GuiLin, Gao XuDong, Lou Min, Wang ChunPing, Yang YongPing, Ceng Zhen. Risk factors for vascular invasion of primary liver cancer[J]. Journal of Clinical Hepatology, 2018, 34(5): 1038-1041. doi: 10.3969/j.issn.1001-5256.2018.05.022
[15]	Ai YeQing, Zhang ChengHua, Liu HuiFang. Risk factors for postoperative pulmonary infection in patients with primary liver cancer[J]. Journal of Clinical Hepatology, 2016, 32(7): 1334-1337. doi: 10.3969/j.issn.1001-5256.2016.07.024
[16]	Hu CaiXia, Zheng JiaSheng, Lin Wei, Cui ShiChang. Analysis of risk factors for early recurrence after microwave ablation for primary hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2015, 31(2): 228-231. doi: 10.3969/j.issn.1001-5256.2015.020
[17]	Gao Rui, Liu ZhongJing, Chen Fei, Gao Lei, Jiang ChuanWu. Multivariate regression analysis of risk factors for HBV-related primary liver cancer[J]. Journal of Clinical Hepatology, 2014, 30(4): 370-372. doi: 10.3969/j.issn.1001-5256.2014.04.021
[18]	Yin TianSheng, Yi YaYang, Mao XiXian, Li DeWei. Meta-analysis of risk factors for posthepatectomy liver failure in patients with hepatocellular carcinoma[J]. Journal of Clinical Hepatology, 2014, 30(10): 1009-1014. doi: 10.3969/j.issn.1001-5256.2014.10.009
[19]	Wu XiaoQing, Wan Hong. Causes of liver failure and impact analysis of prognostic risk factors[J]. Journal of Clinical Hepatology, 2013, 29(4): 294-296+304.
[20]	Wang Hong, Wang YingMin, Zhang Bo. Prospective analysis of risk factors for the occurrence of hepatocellular carcinoma in patients with post-hepatitis B cirrhosis[J]. Journal of Clinical Hepatology, 2007, 23(1): 34-35.

Supplements(0)

Cited By

Cited by

Periodical cited type(2)

1.	林龙，居燕飞，陈雅璐，黄丽华，王明刚，蒙健林，王清坚. 大黄灵仙胶囊对大鼠炎性胆管组织miRNA-152-3p、miRNA-221-3p及miRNA-30b表达水平的实验研究. 辽宁中医杂志. 2025(03): 190-193 .
2.	刘春莉，周兴悦，张厚亮. 乙肝病毒X蛋白对肝细胞癌甲硫氨酸腺苷转移酶1A表达的影响. 罕少疾病杂志. 2023(03): 41-42+60 .

Other cited types(0)

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (728) PDF downloads(94)

Advances in the models for predicting the risk of liver cancer during antiviral therapy in patients with chronic hepatitis B

DOI: 10.3969/j.issn.1001-5256.2021.02.039